Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
44.08 CHF | +2.55% | -.--% | -6.91% |
02:58pm | Bristol Myers: presents advances in lung cancer | CF |
02/06 | Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes | RE |
Sales 2024 * | 4.61TCr 4.13TCr 3,82800Cr | Sales 2025 * | 4.61TCr 4.12TCr 3,82600Cr | Capitalization | 8.33TCr 7.46TCr 6,91900Cr |
---|---|---|---|---|---|
Net income 2024 * | -541.4Cr -484.85Cr -45TCr | Net income 2025 * | 1.02TCr 915.25Cr 85TCr | EV / Sales 2024 * | 2.65 x |
Net Debt 2024 * | 3.9TCr 3.5TCr 3,24200Cr | Net Debt 2025 * | 3.17TCr 2.84TCr 2,63100Cr | EV / Sales 2025 * | 2.5 x |
P/E ratio 2024 * |
-15.6
x | P/E ratio 2025 * |
7.77
x | Employees | - |
Yield 2024 * |
5.86% | Yield 2025 * |
6.15% | Free-Float | 69.27% |
Latest transcript on Bristol-Myers Squibb Company
1 day | +2.55% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 01/15/01 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 20/19/20 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 20/19/20 |
Peter Arduini
BRD | Director/Board Member | 59 | 01/16/01 |
Derica Rice
BRD | Director/Board Member | 59 | 01/20/01 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.35% | 74TCr | |
+32.34% | 60TCr | |
-6.05% | 35TCr | |
+17.24% | 32TCr | |
+3.37% | 28TCr | |
+16.47% | 24TCr | |
+9.26% | 21TCr | |
-5.07% | 21TCr | |
+5.84% | 16TCr |
- Stock Market
- Equities
- BMY Stock
- BMY Stock